In Silico Drug Safety and Efficacy Symposium in Oxford.

On 21st-22nd September 2017, the “In Silico Drug Safety and Efficacy Symposium” was hosted by the Computational Cardiovascular Science team at the Department of Computer Science, University of Oxford. The event was organised in the context of the “In Silico human drug safety and efficacy” project, funded by the National Centre for the Replacement, Refinement & Reduction of Animals in Research, and additionally supported by the UK QSP Network, the Wellcome Trust and the University of Oxford.

The number of delegates reached almost 100, a perfect size that allowed both an easy networking with key experts on the field and a good overview of current trends on scientific disciplines, experimental approaches and regulatory perspectives involved on drug safety and efficacy. The programme covered one day and a half of presentations and discussions, meals and a social dinner event, which allowed the attendees to discuss ideas and collaborative alliances with the key stakeholders.

The symposium demonstrated the significant development and uptake that in silico methodologies are experiencing in their application to drug safety and efficacy. All key players in the field, including representatives from industry, academia, hospitals and regulatory agencies, presented their latest advances and perspectives on the use of in silico modelling to investigate cardiotoxicity, cardiac contractility or drug safety.

The full program of the event can be found here

Confirmed participants included:



Regulatory agencies

Associated initiatives: